LFMD

LifeMD's stock price has seen a significant decline, decreasing approximately 58.82% over the past year and 24.86% over the last six months. Key events impacting the stock include the Q2 2026 earnings release on August 5, 2026, where the company reported an adjusted EPS of -$0.16 and revenue of $47.3 million, both missing analyst estimates, leading to a stock price drop and reduced full-year guidance. The transition from compounded GLP-1 medications to branded therapies, while improving gross margins, resulted in increased customer acquisition costs and lower upfront collections, negatively impacting short-term profitability and contributing to an adjusted EBITDA loss in Q2 2026. The Q1 2026 earnings release on May 6, 2026, also reported an EPS of -$0.20, missing estimates. Positive events include a partnership with AT&T on September 15, 2026, making AT&T the first carrier to offer free access to virtual healthcare powered by LifeMD to its customers, and a dividend declaration on September 22, 2026, on its Series A Cumulative Perpetual Preferred Stock. Analyst outlooks have also shifted, with some no longer forecasting the company to break even in the foreseeable future.